Daniel E. Cohen,Kenneth B. Idler,Jeffrey F. Waring,Emily O. Dumas,Sandeep Dutta
申请号：
US14208266
公开号：
US20160228496A1
申请日:
2014.03.13
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine methylation status of a CpG island within a promoter region of the IL28B gene. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, therapeutic agent 3, an inhibitor of cytochrome P450 (e.g., ritonavir), and/or ribavirin.
